ALK ALK FUSION F1245C

在成神经细胞瘤中,F1245是三个高频率发现的热点ALK突变之一。在一个案例研究中,一个EML4-ALK F1245C突变的预处理非小细胞肺癌(NSCLC)患者在环唑替尼治疗过程中,在疾病进展缓慢后,对铈替尼的反应良好。尽管在环唑替尼治疗前并未对alk重排进行测序,但环唑替尼的耐药性归因于F1245C突变。患者在环唑替尼治疗期间疾病进展缓慢,反映了临床前的发现,表明与单纯融合相比,与F1245C融合的ALK对环唑替尼具有中度抵抗力。
In neuroblastoma, F1245 is one of three hotspot ALK mutations found at a high frequency. In a case study, a pretreated non-small cell lung cancer (NSCLC) patient with EML4-ALK F1245C mutation responded well to ceritinib after slow disease progression during crizotinib treatment. Crizotinib resistance was attributed to the F1245C mutation, although the ALK-rearrangement was not sequenced prior to crizotinib treatment. The patient's slow onset of disease progression during crizotinib treatment mirrors preclinical findings that indicate ALK-fusion with F1245C has moderate resistance to crizotinib compared to the fusion alone.

别名

RS863225283,ALK FUSION PHE1245CYS
Allele Registry ID:CA279597
ClinVar ID:217856

突变位点

Ref. Build: GRCh37   Ensembl Version: 75
Chr.StartStopRef. sVar. Bases
22943685929436859AC
Transcript
ENST00000389048.3

基因序列

NM_004304.4:c.3734T>003eG
NP_004295.2:p.Phe1245Cys
NC_000002.11:g.29436859A>003eC
ENST00000389048.3:c.3734T>003eG